Eli Lilly (LLY) Cash & Equivalents Growth (5y) (2014 - 2026)

Eli Lilly (LLY) Cash & Equivalents Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 11.96%
Dec 31, 2025 14.72%
Sep 30, 2025 22.19%
Jun 30, 2025 7.38%
Mar 31, 2025 12.73%
Dec 31, 2024 6.93%
Sep 30, 2024 16.59%
Jun 30, 2024 7.08%
Mar 31, 2024 3.85%
Dec 31, 2023 -18.83%
Sep 30, 2023 -23.28%
Jun 30, 2023 -16.94%
Mar 31, 2023 2.83%
Dec 31, 2022 -20.57%
Sep 30, 2022 -6.81%
Jun 30, 2022 -3.10%
Mar 31, 2022 -1.24%
Dec 31, 2021 -3.58%
Sep 30, 2021 1.66%
Jun 30, 2021 -0.11%